Stock comparison
Amphastar Pharmaceuticals
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
AMPH
Amphastar Pharmaceuticals
Market cap
$811.75M
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | AMPH | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 54C | 75B | IDXX |
| Benjamin Graham | 50C | 80A | IDXX |
| Philip Fisher | 50C | 75B | IDXX |
| Peter Lynch | 40D | 71B | IDXX |
| Joel Greenblatt | 22F | 83C | IDXX |
| Charlie Munger | 44D | 87A | IDXX |
| Terry Smith | 50D | 84A | IDXX |
Side-by-side metrics
| Metric | AMPH | IDXX |
|---|---|---|
| Market cap | $811.75M | $44.12B |
| P/E (TTM) | 10.6x | 39.0x |
| EV/EBIT | 5.1x | 31.6x |
| ROIC (TTM) | 6.02% | 40.66% |
| Gross margin | 47.34% | 62.05% |
| Net margin | 11.0% | 24.63% |
| Revenue CAGR 5y | 13.24% | 7.56% |
| EPS CAGR 5y | 12.74% | 10.79% |
| Debt / Equity | 0.1x | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
AMPH leads on
- Debt / Equity0.1xvs 0.7x+86%
- EV/EBIT5.1xvs 31.6x+84%
- P/E (TTM)10.6xvs 39.0x+73%
- Revenue CAGR 5y13.24%vs 7.56%+43%
IDXX leads on
- Market cap$44.12Bvs $811.75M+98%
- ROIC (TTM)40.66%vs 6.02%+85%
- Net margin24.63%vs 11.0%+55%
- Gross margin62.05%vs 47.34%+24%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.